KRAS and pancreatic intraductal papillary-mucinous neoplasm: On pooled analysis, KRAS and GNAS mutations were 60.9 % (95 % CI 54.3–67.1) and 55.8 % (95 % CI 48.5–62.8) in IPMN patients (Table 3).